Trading halted as Radient Pharmaceuticals Receives NYSE Amex Approval for Debt to Equity Exchange

Print E-mail
By Staff and canada viagra Wire Reports   
Friday, 07 January 2011 09:50
Shares of Radient Pharmaceuticals Corporation (AMEX:RPC) were halted by officials this morning.


Over 1 million shares had traded hands during pre-market hours this morning before Amex officials halted trading in the cialis 30 mg stock. The company specializing in the research, development, and international commercialization of In Vitro Diagnostic cancer tests, announced today it has received approval from the buy cialis on line New York Stock Exchange AMEX to issue RPC common stock pursuant to proposals approved by RPC's shareholders on December 3, 2010.

According to RPC Chairman and cialis online pharmacy CEO Douglas MacLellan, "We are pleased with the cialis non prescription NYSE Amex approval and viagra on line believe this sets the canada meds viagra Company and cialis india pharmacy on a solid path for the future growth and usa cialis financial stability. Based upon shareholder and soft cialis NYSE Amex approval of the various note transactions, warrant conversions and buy cialis online canada debt exchange agreements, RPC is in a position to have up to approximately $27 million in debt and cialis profesional $14 million in other liabilities eliminated. As a result, we anticipate an increase of approximately $41 million in total shareholder's equity."

BioMedReports ran a special report about the company this morning.

It can be found here: http://biomedreports.com/2011010762156/radient-positioned-to-deliver-significant-cancer-test-profits.html





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
BioMedReports Boston Strategics Corp. Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent "FF-10501": Below is a loo... http://t.co/N22zWingRP
17hreplyretweetfavorite
BioMedReports FDA Approves ELELYSO(TM); Auxilium To Present CCH Data For AUX-CC-867 MULTICORD: Below is a look at some of t... http://t.co/38kIFa08zF
BioMedReports Team identifies possible bacterial drivers of inflammatory bowel diseases http://t.co/kqjKEssVCp
navigation
Benzinga.com supporter Seeking Alpha Certified